These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 12829768)

  • 1. Medicine. The need for a global HIV vaccine enterprise.
    Klausner RD; Fauci AS; Corey L; Nabel GJ; Gayle H; Berkley S; Haynes BF; Baltimore D; Collins C; Douglas RG; Esparza J; Francis DP; Ganguly NK; Gerberding JL; Johnston MI; Kazatchkine MD; McMichael AJ; Makgoba MW; Pantaleo G; Piot P; Shao Y; Tramont E; Varmus H; Wasserheit JN
    Science; 2003 Jun; 300(5628):2036-9. PubMed ID: 12829768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The challenges of an HIV vaccine enterprise.
    Wolf H
    Science; 2004 Feb; 303(5662):1294-7; author reply 1294-7. PubMed ID: 14991961
    [No Abstract]   [Full Text] [Related]  

  • 3. G-8 endorses new global HIV vaccine enterprise.
    Bull World Health Organ; 2004 Jul; 82(7):557. PubMed ID: 15500292
    [No Abstract]   [Full Text] [Related]  

  • 4. Funding support lacking in search for HIV vaccine.
    AIDS Alert; 1999 Jan; 14(1):5-7. PubMed ID: 11366091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Market incentives, human lives, and AIDS vaccines.
    Craddock S
    Soc Sci Med; 2007 Mar; 64(5):1042-56. PubMed ID: 17113203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An HIV/AIDS vaccine: where do we go from here?
    Bernstein A
    Trends Microbiol; 2008 Dec; 16(12):553-4. PubMed ID: 18964019
    [No Abstract]   [Full Text] [Related]  

  • 7. Estimating the demand for a preventive HIV vaccine: why we need to do better. Reliable estimates would help in achieving several policy and advocacy objectives.
    Hecht R; Suraratdecha C
    PLoS Med; 2006 Sep; 3(10):e398. PubMed ID: 16953657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global health public-private partnerships: IAVI, partnerships and capacity building.
    Hanlin R; Chataway J; Smith J
    Afr J Med Med Sci; 2007; 36 Suppl():69-75. PubMed ID: 17703568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 vaccine clinical trials: the Brazilian experience.
    Ersching J; Pinto AR
    Rev Med Virol; 2009 Sep; 19(5):301-11. PubMed ID: 19650156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Private investment in AIDS vaccine development: obstacles and solutions.
    Batson A; Ainsworth M
    Bull World Health Organ; 2001; 79(8):721-7. PubMed ID: 11545328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New institute to focus on AIDS vaccine.
    AIDS Read; 2008 Nov; 18(11):551. PubMed ID: 19058408
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV vaccine efficacy trials: towards the future of HIV prevention.
    Kim D; Elizaga M; Duerr A
    Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panel discussion on vaccine development to meet U.S. and international needs. Strategies for reducing the disincentives to HIV vaccine development: description of a successful public-private sector international collaboration.
    Bronnenkant L
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S311-3. PubMed ID: 7865329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statistical evaluation of HIV vaccines in early clinical trials.
    Moodie Z; Rossini AJ; Hudgens MG; Gilbert PB; Self SG; Russell ND
    Contemp Clin Trials; 2006 Apr; 27(2):147-60. PubMed ID: 16426900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The challenges of HIV vaccine development and testing.
    Burgers WA; Williamson C
    Best Pract Res Clin Obstet Gynaecol; 2005 Apr; 19(2):277-91. PubMed ID: 15778116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The International AIDS Vaccine Initiative.
    Berkley S
    J Int Assoc Physicians AIDS Care; 1997 Nov; 3(11):30-4. PubMed ID: 11364811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Vaccines against HIV].
    Holm-Hansen C
    Tidsskr Nor Laegeforen; 2006 Nov; 126(23):3117-20. PubMed ID: 17160118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of primate models for AIDS.
    Haigwood NL
    AIDS Rev; 2004; 6(4):187-98. PubMed ID: 15700617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why we don't have an HIV vaccine, and how we can develop one.
    Harris JE
    Health Aff (Millwood); 2009; 28(6):1642-54. PubMed ID: 19887405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Support for the RV144 HIV vaccine trial.
    AIDS Vaccine Advocacy Coalition
    Science; 2004 Jul; 305(5681):177-80; author reply 177-80. PubMed ID: 15250069
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.